Literature DB >> 17240282

Adjudication of serious heart failure in patients from PROactive.

Lars Rydén, Inga Thráinsdóttir, Karl Swedberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17240282     DOI： 10.1016/S0140-6736(07)60106-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.

Authors:  Huamei He; Hai Tao; Hui Xiong; Sheng Zhong Duan; Francis X McGowan; Richard M Mortensen; James A Balschi
Journal:  Toxicol Sci       Date:  2014-01-21       Impact factor: 4.849

2.  Heart failure event definitions in drug trials in patients with type 2 diabetes.

Authors:  Abhinav Sharma; Deepak L Bhatt; Gonzalo Calvo; Nancy J Brown; Faiez Zannad; Robert J Mentz
Journal:  Lancet Diabetes Endocrinol       Date:  2016-04       Impact factor: 32.069

Review 3.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Muhammad Shahzeb Khan; George L Bakris; Matthew R Weir; Jonathan H Seltzer; Naveed Sattar; Darren K McGuire; James L Januzzi; Norman Stockbridge; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2018-03-10       Impact factor: 24.094

Review 4.  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Authors:  Eberhard Standl; Oliver Schnell; Darren K McGuire
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 5.  Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.

Authors:  C A Alvarez; I Lingvay; V Vuylsteke; R L Koffarnus; D K McGuire
Journal:  Clin Pharmacol Ther       Date:  2015-07-03       Impact factor: 6.875

Review 6.  Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.

Authors:  Shilpa Vijayakumar; Muthiah Vaduganathan; Javed Butler
Journal:  Circulation       Date:  2018-03-06       Impact factor: 29.690

Review 7.  Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach.

Authors:  Josephine L Harrington; Natalia de Albuquerque Rocha; Kershaw V Patel; Subodh Verma; Darren K McGuire
Journal:  Curr Diab Rep       Date:  2018-07-14       Impact factor: 4.810

Review 8.  Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Authors:  John Dormandy; Mondira Bhattacharya; Anne-Ruth van Troostenburg de Bruyn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.

Authors:  Martin Lorenz; Francesca Lawson; David Owens; Denis Raccah; Christine Roy-Duval; Anne Lehmann; Riccardo Perfetti; Lawrence Blonde
Journal:  Cardiovasc Diabetol       Date:  2017-01-13       Impact factor: 9.951

Review 10.  PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Authors:  Erland Erdmann; John Dormandy; Robert Wilcox; Massimo Massi-Benedetti; Bernard Charbonnel
Journal:  Vasc Health Risk Manag       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.